Utilization of epidermal growth factor receptor (EGFR) testing in the United States: a case study of T3 translational research View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2013-02-28

AUTHORS

Julie A. Lynch, Muin J. Khoury, Ann Borzecki, Jerry Cromwell, Laura L. Hayman, Pat Reid Ponte, Glenn A. Miller, Christopher S. Lathan

ABSTRACT

Purpose:We examined hospital use of the epidermal growth factor receptor assay in patients with lung cancer in the United States. Our goal was to inform the development of a model to predict phase 3 translation of guideline-directed molecular diagnostic tests.Methods:This was a retrospective observational study. Using logistic regression, we analyzed the association between hospitals’ institutional and regional characteristics and the likelihood that an epidermal growth factor receptor assay would be ordered.Results:Significant institutional predictors included affiliation with an academic medical center (odds ratio, 1.48; 95% confidence interval, 1.20–1.83), participation in a National Cancer Institute clinical research cooperative group (odds ratio, 2.06, 1.66–2.55), and ­availability of positron emission tomography scan (odds ratio, 1.44, 1.07–1.94) and cardiothoracic surgery (odds ratio, 1.90, 1.52–2.37) services. Significant regional predictors included metropolitan county (odds ratio, 2.08, 1.48–2.91), population with above-average education (odds ratio, 1.46, 1.09–1.96), and population with above-average income (odds ratio, 1.46, 1.04–2.05). Distance from a National Cancer Institute cancer center was a negative predictor (odds ratio, 0.996, 0.995–0.998), with a 34% decrease in likelihood for every 100 miles.Conclusion:In 2010, only 12% of US acute-care hospitals ordered the epidermal growth factor receptor assay, suggesting that most patients with lung cancer did not have access to this test. This case study illustrated the need for: (i) increased dissemination and implementation research, and (ii) interventions to improve adoption of guideline-directed molecular diagnostic tests by community hospitals.Genet Med 2013:15(8):630–638 More... »

PAGES

630-638

Identifiers

URI

http://scigraph.springernature.com/pub.10.1038/gim.2013.5

DOI

http://dx.doi.org/10.1038/gim.2013.5

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1051257040

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/23448725


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cross-Sectional Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Delivery of Health Care", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "ErbB Receptors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Genetic Testing", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Genomics", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Guidelines as Topic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Logistic Models", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Lung Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Molecular Diagnostic Techniques", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Mutation", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Retrospective Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Translational Medical Research", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "United States", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Veterans Health Administration, Center for Health Quality, Outcomes, and Economic Research, Bedford, Massachusetts, USA", 
          "id": "http://www.grid.ac/institutes/grid.239186.7", 
          "name": [
            "Veterans Health Administration, University of Massachusetts Boston & Dana Farber Cancer Institute, Boston, Massachusetts, USA", 
            "Veterans Health Administration, Center for Health Quality, Outcomes, and Economic Research, Bedford, Massachusetts, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Lynch", 
        "givenName": "Julie A.", 
        "id": "sg:person.0674353541.09", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0674353541.09"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Office of Public Health Genomics, CDC, Epidemiology and Genomics Research Program, NCI, Bethesda, Maryland, USA", 
          "id": "http://www.grid.ac/institutes/grid.48336.3a", 
          "name": [
            "Office of Public Health Genomics, CDC, Epidemiology and Genomics Research Program, NCI, Bethesda, Maryland, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Khoury", 
        "givenName": "Muin J.", 
        "id": "sg:person.0745141262.84", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0745141262.84"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Veterans Health Administration, Center for Health Quality, Outcomes, and Economic Research, Bedford, Massachusetts, USA", 
          "id": "http://www.grid.ac/institutes/grid.239186.7", 
          "name": [
            "Veterans Health Administration, Center for Health Quality, Outcomes, and Economic Research, Bedford, Massachusetts, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Borzecki", 
        "givenName": "Ann", 
        "id": "sg:person.01300534376.71", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01300534376.71"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Massachusetts Boston & Research Triangle Institute, Boston, Massachusetts, USA", 
          "id": "http://www.grid.ac/institutes/grid.266685.9", 
          "name": [
            "University of Massachusetts Boston & Research Triangle Institute, Boston, Massachusetts, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Cromwell", 
        "givenName": "Jerry", 
        "id": "sg:person.0646730066.28", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0646730066.28"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Massachusetts Boston, Boston, Massachusetts, USA", 
          "id": "http://www.grid.ac/institutes/grid.266685.9", 
          "name": [
            "University of Massachusetts Boston, Boston, Massachusetts, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hayman", 
        "givenName": "Laura L.", 
        "id": "sg:person.01223052734.95", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01223052734.95"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Dana Farber Cancer Institute, Boston, Massachusetts, USA", 
          "id": "http://www.grid.ac/institutes/grid.65499.37", 
          "name": [
            "Dana Farber Cancer Institute, Boston, Massachusetts, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ponte", 
        "givenName": "Pat Reid", 
        "id": "sg:person.01246451666.93", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01246451666.93"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Present address: AstraZeneca Pharmaceutical LP, Wilmington, Delaware, USA", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Genzyme Genetics, Santa Fe, New Mexico, USA", 
            "Present address: AstraZeneca Pharmaceutical LP, Wilmington, Delaware, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Miller", 
        "givenName": "Glenn A.", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Dana Farber Cancer Institute, Boston, Massachusetts, USA", 
          "id": "http://www.grid.ac/institutes/grid.65499.37", 
          "name": [
            "Dana Farber Cancer Institute, Boston, Massachusetts, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Lathan", 
        "givenName": "Christopher S.", 
        "id": "sg:person.015453551547.59", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015453551547.59"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1038/gim.2011.12", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1000617109", 
          "https://doi.org/10.1038/gim.2011.12"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1097/gim.0b013e3182091ba4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1034208612", 
          "https://doi.org/10.1097/gim.0b013e3182091ba4"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1097/gim.0b013e31815699d0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1005040153", 
          "https://doi.org/10.1097/gim.0b013e31815699d0"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/489052a", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1044958056", 
          "https://doi.org/10.1038/489052a"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/gm308", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1051017326", 
          "https://doi.org/10.1186/gm308"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00439-011-1028-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013700453", 
          "https://doi.org/10.1007/s00439-011-1028-3"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2013-02-28", 
    "datePublishedReg": "2013-02-28", 
    "description": "Purpose:We examined hospital use of the epidermal growth factor receptor assay in patients with lung cancer in the United States. Our goal was to inform the development of a model to predict phase 3 translation of guideline-directed molecular diagnostic tests.Methods:This was a retrospective observational study. Using logistic regression, we analyzed the association between hospitals\u2019 institutional and regional characteristics and the likelihood that an epidermal growth factor receptor assay would be ordered.Results:Significant institutional predictors included affiliation with an academic medical center (odds ratio, 1.48; 95% confidence interval, 1.20\u20131.83), participation in a National Cancer Institute clinical research cooperative group (odds ratio, 2.06, 1.66\u20132.55), and \u00adavailability of positron emission tomography scan (odds ratio, 1.44, 1.07\u20131.94) and cardiothoracic surgery (odds ratio, 1.90, 1.52\u20132.37) services. Significant regional predictors included metropolitan county (odds ratio, 2.08, 1.48\u20132.91), population with above-average education (odds ratio, 1.46, 1.09\u20131.96), and population with above-average income (odds ratio, 1.46, 1.04\u20132.05). Distance from a National Cancer Institute cancer center was a negative predictor (odds ratio, 0.996, 0.995\u20130.998), with a 34% decrease in likelihood for every 100 miles.Conclusion:In 2010, only 12% of US acute-care hospitals ordered the epidermal growth factor receptor assay, suggesting that most patients with lung cancer did not have access to this test. This case study illustrated the need for: (i) increased dissemination and implementation research, and (ii) interventions to improve adoption of guideline-directed molecular diagnostic tests by community hospitals.Genet Med 2013:15(8):630\u2013638", 
    "genre": "article", 
    "id": "sg:pub.10.1038/gim.2013.5", 
    "inLanguage": "en", 
    "isAccessibleForFree": true, 
    "isFundedItemOf": [
      {
        "id": "sg:grant.2705226", 
        "type": "MonetaryGrant"
      }, 
      {
        "id": "sg:grant.2699130", 
        "type": "MonetaryGrant"
      }, 
      {
        "id": "sg:grant.2403535", 
        "type": "MonetaryGrant"
      }
    ], 
    "isPartOf": [
      {
        "id": "sg:journal.1119411", 
        "issn": [
          "1098-3600", 
          "1530-0366"
        ], 
        "name": "Genetics in Medicine", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "8", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "15"
      }
    ], 
    "keywords": [
      "molecular diagnostic tests", 
      "lung cancer", 
      "epidermal growth factor receptor (EGFR) testing", 
      "receptor assay", 
      "positron emission tomography scan", 
      "diagnostic tests", 
      "US acute care hospitals", 
      "retrospective observational study", 
      "emission tomography scan", 
      "National Cancer Institute cancer center", 
      "acute care hospitals", 
      "Research Cooperative Group", 
      "academic medical center", 
      "epidermal growth factor receptor", 
      "growth factor receptor", 
      "most patients", 
      "receptor testing", 
      "Cancer Center", 
      "tomography scan", 
      "community hospital", 
      "observational study", 
      "Medical Center", 
      "hospital use", 
      "logistic regression", 
      "hospital", 
      "factor receptor", 
      "translational research", 
      "negative predictor", 
      "implementation research", 
      "cooperative groups", 
      "patients", 
      "cancer", 
      "predictors", 
      "United States", 
      "metropolitan counties", 
      "assays", 
      "regional predictors", 
      "population", 
      "study", 
      "receptors", 
      "intervention", 
      "scans", 
      "above-average income", 
      "test", 
      "likelihood", 
      "center", 
      "association", 
      "MED", 
      "group", 
      "regression", 
      "dissemination", 
      "institutional predictors", 
      "decrease", 
      "testing", 
      "County", 
      "use", 
      "need", 
      "access", 
      "development", 
      "participation", 
      "research", 
      "services", 
      "education", 
      "utilization", 
      "income", 
      "characteristics", 
      "goal", 
      "translation", 
      "state", 
      "model", 
      "regional characteristics", 
      "adoption", 
      "affiliation", 
      "miles", 
      "case study", 
      "distance", 
      "epidermal growth factor receptor assay", 
      "growth factor receptor assay", 
      "factor receptor assay", 
      "phase 3 translation", 
      "guideline-directed molecular diagnostic tests", 
      "Significant institutional predictors", 
      "National Cancer Institute clinical research cooperative group", 
      "Cancer Institute clinical research cooperative group", 
      "Institute clinical research cooperative group", 
      "clinical research cooperative group", 
      "Significant regional predictors", 
      "above-average education", 
      "Cancer Institute cancer center", 
      "Institute cancer center", 
      "Genet Med", 
      "growth factor receptor (EGFR) testing", 
      "factor receptor (EGFR) testing", 
      "T3 translational research"
    ], 
    "name": "Utilization of epidermal growth factor receptor (EGFR) testing in the United States: a case study of T3 translational research", 
    "pagination": "630-638", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1051257040"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1038/gim.2013.5"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "23448725"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1038/gim.2013.5", 
      "https://app.dimensions.ai/details/publication/pub.1051257040"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2021-12-01T19:28", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20211201/entities/gbq_results/article/article_594.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1038/gim.2013.5"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1038/gim.2013.5'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1038/gim.2013.5'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1038/gim.2013.5'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1038/gim.2013.5'


 

This table displays all metadata directly associated to this object as RDF triples.

306 TRIPLES      22 PREDICATES      140 URIs      126 LITERALS      21 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1038/gim.2013.5 schema:about N3478402d96a9484abfc20a87674b5a5b
2 N365274df25ed4b309930369810e1c013
3 N54cb517800f949faa41d716e9be9b6ee
4 N6f4b9982ff6e47cdb7135aa9d9d7b182
5 N813ab77ac7874c25a592a0a09e09e625
6 N8b6f188ed812480380489ed2ebece2f1
7 N9dc89665c5df48f6a42de1125ab7e700
8 Na9fee0379a254704b06fb4216930c8f3
9 Nb3fbb98152ae4c6ea968c7e17f285205
10 Ndd919530372b4dd19d150d95421be39d
11 Ndeef042cb2d5455ca1b9724c3e83fdc6
12 Ne68b73ce47204c87b833d989fe32b682
13 Ned5c5faf31f944609b548124fcf4ffa9
14 Nedbbb7a939a6458398e3e71d08e744a6
15 anzsrc-for:11
16 anzsrc-for:1103
17 schema:author Nd003f924a65c408599214406921dea5c
18 schema:citation sg:pub.10.1007/s00439-011-1028-3
19 sg:pub.10.1038/489052a
20 sg:pub.10.1038/gim.2011.12
21 sg:pub.10.1097/gim.0b013e31815699d0
22 sg:pub.10.1097/gim.0b013e3182091ba4
23 sg:pub.10.1186/gm308
24 schema:datePublished 2013-02-28
25 schema:datePublishedReg 2013-02-28
26 schema:description Purpose:We examined hospital use of the epidermal growth factor receptor assay in patients with lung cancer in the United States. Our goal was to inform the development of a model to predict phase 3 translation of guideline-directed molecular diagnostic tests.Methods:This was a retrospective observational study. Using logistic regression, we analyzed the association between hospitals’ institutional and regional characteristics and the likelihood that an epidermal growth factor receptor assay would be ordered.Results:Significant institutional predictors included affiliation with an academic medical center (odds ratio, 1.48; 95% confidence interval, 1.20–1.83), participation in a National Cancer Institute clinical research cooperative group (odds ratio, 2.06, 1.66–2.55), and ­availability of positron emission tomography scan (odds ratio, 1.44, 1.07–1.94) and cardiothoracic surgery (odds ratio, 1.90, 1.52–2.37) services. Significant regional predictors included metropolitan county (odds ratio, 2.08, 1.48–2.91), population with above-average education (odds ratio, 1.46, 1.09–1.96), and population with above-average income (odds ratio, 1.46, 1.04–2.05). Distance from a National Cancer Institute cancer center was a negative predictor (odds ratio, 0.996, 0.995–0.998), with a 34% decrease in likelihood for every 100 miles.Conclusion:In 2010, only 12% of US acute-care hospitals ordered the epidermal growth factor receptor assay, suggesting that most patients with lung cancer did not have access to this test. This case study illustrated the need for: (i) increased dissemination and implementation research, and (ii) interventions to improve adoption of guideline-directed molecular diagnostic tests by community hospitals.Genet Med 2013:15(8):630–638
27 schema:genre article
28 schema:inLanguage en
29 schema:isAccessibleForFree true
30 schema:isPartOf N294f1b2555f04dcc81d9753da0378635
31 N42708f281e2349c7a41a5ad2f42b6cb6
32 sg:journal.1119411
33 schema:keywords Cancer Center
34 Cancer Institute cancer center
35 Cancer Institute clinical research cooperative group
36 County
37 Genet Med
38 Institute cancer center
39 Institute clinical research cooperative group
40 MED
41 Medical Center
42 National Cancer Institute cancer center
43 National Cancer Institute clinical research cooperative group
44 Research Cooperative Group
45 Significant institutional predictors
46 Significant regional predictors
47 T3 translational research
48 US acute care hospitals
49 United States
50 above-average education
51 above-average income
52 academic medical center
53 access
54 acute care hospitals
55 adoption
56 affiliation
57 assays
58 association
59 cancer
60 case study
61 center
62 characteristics
63 clinical research cooperative group
64 community hospital
65 cooperative groups
66 decrease
67 development
68 diagnostic tests
69 dissemination
70 distance
71 education
72 emission tomography scan
73 epidermal growth factor receptor
74 epidermal growth factor receptor (EGFR) testing
75 epidermal growth factor receptor assay
76 factor receptor
77 factor receptor (EGFR) testing
78 factor receptor assay
79 goal
80 group
81 growth factor receptor
82 growth factor receptor (EGFR) testing
83 growth factor receptor assay
84 guideline-directed molecular diagnostic tests
85 hospital
86 hospital use
87 implementation research
88 income
89 institutional predictors
90 intervention
91 likelihood
92 logistic regression
93 lung cancer
94 metropolitan counties
95 miles
96 model
97 molecular diagnostic tests
98 most patients
99 need
100 negative predictor
101 observational study
102 participation
103 patients
104 phase 3 translation
105 population
106 positron emission tomography scan
107 predictors
108 receptor assay
109 receptor testing
110 receptors
111 regional characteristics
112 regional predictors
113 regression
114 research
115 retrospective observational study
116 scans
117 services
118 state
119 study
120 test
121 testing
122 tomography scan
123 translation
124 translational research
125 use
126 utilization
127 schema:name Utilization of epidermal growth factor receptor (EGFR) testing in the United States: a case study of T3 translational research
128 schema:pagination 630-638
129 schema:productId N55da8898b0da499f8a5ce461e36033d3
130 Nbac2442593b6416e815227cb093e364e
131 Nbbcb10e4c24e497b8806c7e52b2687cc
132 schema:sameAs https://app.dimensions.ai/details/publication/pub.1051257040
133 https://doi.org/10.1038/gim.2013.5
134 schema:sdDatePublished 2021-12-01T19:28
135 schema:sdLicense https://scigraph.springernature.com/explorer/license/
136 schema:sdPublisher N7bf161f938dc429483c22a8866f404ac
137 schema:url https://doi.org/10.1038/gim.2013.5
138 sgo:license sg:explorer/license/
139 sgo:sdDataset articles
140 rdf:type schema:ScholarlyArticle
141 N1f5f7a24bb844f3896f59dcacd774719 rdf:first sg:person.01300534376.71
142 rdf:rest N3b398b873ff2409d9bb2af55b2685640
143 N294f1b2555f04dcc81d9753da0378635 schema:issueNumber 8
144 rdf:type schema:PublicationIssue
145 N3478402d96a9484abfc20a87674b5a5b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
146 schema:name Mutation
147 rdf:type schema:DefinedTerm
148 N365274df25ed4b309930369810e1c013 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
149 schema:name Delivery of Health Care
150 rdf:type schema:DefinedTerm
151 N3b398b873ff2409d9bb2af55b2685640 rdf:first sg:person.0646730066.28
152 rdf:rest Nce52fc0d781d46749b64a64d50c4619d
153 N42708f281e2349c7a41a5ad2f42b6cb6 schema:volumeNumber 15
154 rdf:type schema:PublicationVolume
155 N54cb517800f949faa41d716e9be9b6ee schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
156 schema:name Cross-Sectional Studies
157 rdf:type schema:DefinedTerm
158 N55da8898b0da499f8a5ce461e36033d3 schema:name dimensions_id
159 schema:value pub.1051257040
160 rdf:type schema:PropertyValue
161 N6f4b9982ff6e47cdb7135aa9d9d7b182 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
162 schema:name Retrospective Studies
163 rdf:type schema:DefinedTerm
164 N7bf161f938dc429483c22a8866f404ac schema:name Springer Nature - SN SciGraph project
165 rdf:type schema:Organization
166 N813ab77ac7874c25a592a0a09e09e625 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
167 schema:name Humans
168 rdf:type schema:DefinedTerm
169 N8b6f188ed812480380489ed2ebece2f1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
170 schema:name Genomics
171 rdf:type schema:DefinedTerm
172 N9dc89665c5df48f6a42de1125ab7e700 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
173 schema:name ErbB Receptors
174 rdf:type schema:DefinedTerm
175 Na9fee0379a254704b06fb4216930c8f3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
176 schema:name Genetic Testing
177 rdf:type schema:DefinedTerm
178 Nafdef0a2533842ec94b89b48c987f464 schema:affiliation grid-institutes:None
179 schema:familyName Miller
180 schema:givenName Glenn A.
181 rdf:type schema:Person
182 Nb0451acc5cb34ae8a7d45eb7f95e7b5f rdf:first Nafdef0a2533842ec94b89b48c987f464
183 rdf:rest Nbbc149740e1d4ef693af05f00dce3258
184 Nb3fbb98152ae4c6ea968c7e17f285205 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
185 schema:name Lung Neoplasms
186 rdf:type schema:DefinedTerm
187 Nbac2442593b6416e815227cb093e364e schema:name doi
188 schema:value 10.1038/gim.2013.5
189 rdf:type schema:PropertyValue
190 Nbbc149740e1d4ef693af05f00dce3258 rdf:first sg:person.015453551547.59
191 rdf:rest rdf:nil
192 Nbbcb10e4c24e497b8806c7e52b2687cc schema:name pubmed_id
193 schema:value 23448725
194 rdf:type schema:PropertyValue
195 Nce52fc0d781d46749b64a64d50c4619d rdf:first sg:person.01223052734.95
196 rdf:rest Nd0c3f1cc98514adfad8f69d9726d3018
197 Nd003f924a65c408599214406921dea5c rdf:first sg:person.0674353541.09
198 rdf:rest Ne343edc0102f47c8bb10f9f0b7600c63
199 Nd0c3f1cc98514adfad8f69d9726d3018 rdf:first sg:person.01246451666.93
200 rdf:rest Nb0451acc5cb34ae8a7d45eb7f95e7b5f
201 Ndd919530372b4dd19d150d95421be39d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
202 schema:name United States
203 rdf:type schema:DefinedTerm
204 Ndeef042cb2d5455ca1b9724c3e83fdc6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
205 schema:name Logistic Models
206 rdf:type schema:DefinedTerm
207 Ne343edc0102f47c8bb10f9f0b7600c63 rdf:first sg:person.0745141262.84
208 rdf:rest N1f5f7a24bb844f3896f59dcacd774719
209 Ne68b73ce47204c87b833d989fe32b682 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
210 schema:name Translational Medical Research
211 rdf:type schema:DefinedTerm
212 Ned5c5faf31f944609b548124fcf4ffa9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
213 schema:name Molecular Diagnostic Techniques
214 rdf:type schema:DefinedTerm
215 Nedbbb7a939a6458398e3e71d08e744a6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
216 schema:name Guidelines as Topic
217 rdf:type schema:DefinedTerm
218 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
219 schema:name Medical and Health Sciences
220 rdf:type schema:DefinedTerm
221 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
222 schema:name Clinical Sciences
223 rdf:type schema:DefinedTerm
224 sg:grant.2403535 http://pending.schema.org/fundedItem sg:pub.10.1038/gim.2013.5
225 rdf:type schema:MonetaryGrant
226 sg:grant.2699130 http://pending.schema.org/fundedItem sg:pub.10.1038/gim.2013.5
227 rdf:type schema:MonetaryGrant
228 sg:grant.2705226 http://pending.schema.org/fundedItem sg:pub.10.1038/gim.2013.5
229 rdf:type schema:MonetaryGrant
230 sg:journal.1119411 schema:issn 1098-3600
231 1530-0366
232 schema:name Genetics in Medicine
233 schema:publisher Springer Nature
234 rdf:type schema:Periodical
235 sg:person.01223052734.95 schema:affiliation grid-institutes:grid.266685.9
236 schema:familyName Hayman
237 schema:givenName Laura L.
238 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01223052734.95
239 rdf:type schema:Person
240 sg:person.01246451666.93 schema:affiliation grid-institutes:grid.65499.37
241 schema:familyName Ponte
242 schema:givenName Pat Reid
243 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01246451666.93
244 rdf:type schema:Person
245 sg:person.01300534376.71 schema:affiliation grid-institutes:grid.239186.7
246 schema:familyName Borzecki
247 schema:givenName Ann
248 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01300534376.71
249 rdf:type schema:Person
250 sg:person.015453551547.59 schema:affiliation grid-institutes:grid.65499.37
251 schema:familyName Lathan
252 schema:givenName Christopher S.
253 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015453551547.59
254 rdf:type schema:Person
255 sg:person.0646730066.28 schema:affiliation grid-institutes:grid.266685.9
256 schema:familyName Cromwell
257 schema:givenName Jerry
258 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0646730066.28
259 rdf:type schema:Person
260 sg:person.0674353541.09 schema:affiliation grid-institutes:grid.239186.7
261 schema:familyName Lynch
262 schema:givenName Julie A.
263 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0674353541.09
264 rdf:type schema:Person
265 sg:person.0745141262.84 schema:affiliation grid-institutes:grid.48336.3a
266 schema:familyName Khoury
267 schema:givenName Muin J.
268 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0745141262.84
269 rdf:type schema:Person
270 sg:pub.10.1007/s00439-011-1028-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013700453
271 https://doi.org/10.1007/s00439-011-1028-3
272 rdf:type schema:CreativeWork
273 sg:pub.10.1038/489052a schema:sameAs https://app.dimensions.ai/details/publication/pub.1044958056
274 https://doi.org/10.1038/489052a
275 rdf:type schema:CreativeWork
276 sg:pub.10.1038/gim.2011.12 schema:sameAs https://app.dimensions.ai/details/publication/pub.1000617109
277 https://doi.org/10.1038/gim.2011.12
278 rdf:type schema:CreativeWork
279 sg:pub.10.1097/gim.0b013e31815699d0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1005040153
280 https://doi.org/10.1097/gim.0b013e31815699d0
281 rdf:type schema:CreativeWork
282 sg:pub.10.1097/gim.0b013e3182091ba4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1034208612
283 https://doi.org/10.1097/gim.0b013e3182091ba4
284 rdf:type schema:CreativeWork
285 sg:pub.10.1186/gm308 schema:sameAs https://app.dimensions.ai/details/publication/pub.1051017326
286 https://doi.org/10.1186/gm308
287 rdf:type schema:CreativeWork
288 grid-institutes:None schema:alternateName Present address: AstraZeneca Pharmaceutical LP, Wilmington, Delaware, USA
289 schema:name Genzyme Genetics, Santa Fe, New Mexico, USA
290 Present address: AstraZeneca Pharmaceutical LP, Wilmington, Delaware, USA
291 rdf:type schema:Organization
292 grid-institutes:grid.239186.7 schema:alternateName Veterans Health Administration, Center for Health Quality, Outcomes, and Economic Research, Bedford, Massachusetts, USA
293 schema:name Veterans Health Administration, Center for Health Quality, Outcomes, and Economic Research, Bedford, Massachusetts, USA
294 Veterans Health Administration, University of Massachusetts Boston & Dana Farber Cancer Institute, Boston, Massachusetts, USA
295 rdf:type schema:Organization
296 grid-institutes:grid.266685.9 schema:alternateName University of Massachusetts Boston & Research Triangle Institute, Boston, Massachusetts, USA
297 University of Massachusetts Boston, Boston, Massachusetts, USA
298 schema:name University of Massachusetts Boston & Research Triangle Institute, Boston, Massachusetts, USA
299 University of Massachusetts Boston, Boston, Massachusetts, USA
300 rdf:type schema:Organization
301 grid-institutes:grid.48336.3a schema:alternateName Office of Public Health Genomics, CDC, Epidemiology and Genomics Research Program, NCI, Bethesda, Maryland, USA
302 schema:name Office of Public Health Genomics, CDC, Epidemiology and Genomics Research Program, NCI, Bethesda, Maryland, USA
303 rdf:type schema:Organization
304 grid-institutes:grid.65499.37 schema:alternateName Dana Farber Cancer Institute, Boston, Massachusetts, USA
305 schema:name Dana Farber Cancer Institute, Boston, Massachusetts, USA
306 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...